New Biotech Innovation Cycle Drives Strong Gains Across Sector

Biotech stocks are rallying this year, driven by successful clinical trials, rising merger and acquisition activity, and new technologies like artificial intelligence, genomics, and messenger RNA. The iShares Biotechnology ETF is up 24% through October 23, following a 28% gain in 2025. Out of the fund's 233 holdings, two dozen have more than doubled year-to-date, led by Moderna with a 587% surge.

Market Drivers

Analysts report a powerful new innovation cycle is underway as companies understand disease biology better and bring newer methods to market. The FDA approved about a dozen novel biologic drugs in 2025 out of 46 total approvals, with roughly 66 novel drugs currently in the pipeline. Major pharmaceutical companies are also facing a patent cliff, with products representing $180 billion in revenue losing exclusivity by 2030, leaving cash-rich firms eager to acquire new products. Biopharma dealmaking hit $134 billion in the first half of 2026, surpassing the $112 billion recorded for all of 2025.

Key Players

Individual companies are seeing massive jumps, with DNA sequencing firm Illumina and biotech instrument provider 10x Genomics both posting major gains. Moderna and Merck are advancing a joint melanoma skin cancer drug that uses mRNA, which showed a 42% reduction in cancer recurrence or death during clinical trials and aims for a 2027 launch. Meanwhile, Eli Lilly advanced its next-generation obesity drug retatrutide, which produced 28% to 30% weight loss in recent trials and is slated for an FDA submission in early 2027. Other treatments are progressing too, including AstraZeneca and Amgen's inflammation drug Tezspire and Roche's thyroid eye disease treatment Enspryng.

Context

The biotechnology sector operates through long development cycles where high failure rates are common before products ever reach the market. The current recovery follows a post-pandemic slump when higher interest rates slowed down investments and demand for early COVID-19 products faded. Today's growth is supported by more advanced technological tools and strong corporate balance sheets in the pharmaceutical industry.